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PURPOSE. The primary aim was to determine optimal test conditions for evaluating dark
adaptation in intermediate age-related macular degeneration (iAMD) in order to minimize test
time while maintaining diagnostic sensitivity.
METHODS. People with AMD and age-similar controls were recruited (aged >55 years). Rod
intercept time (RIT) was assessed after a 76%, 70%, and 65% rhodopsin bleach at 58
eccentricity and 76% and 70% bleach at 128. Test order was randomized and a 30-minute
washout period added between tests. Results were compared between control and iAMD
groups and receiver operating characteristics (ROC) curves were constructed.
RESULTS. A total of 26 participants with variable grades of macular health attended for two
visits. There was a statistically significant difference in average RIT between the control and
iAMD groups at 58 (median, IQR controls ¼ 5.8 minutes, 3.8–7.5; iAMD ¼ 20.6 minutes,
11.1–30.0; Mann-Whitney, P ¼ 0.01) and at 128 (mean, controls: 4.54 minutes 6 2.12 SD,
iAMD ¼ 7.72 minutes 6 3.37 SD; independent samples t-test, P ¼ 0.03) following a 76%
bleach. Area under the ROC curves was 0.83 (confidence interval [CI]: 0.64–1.0) and 0.79 (CI:
0.59–0.99) for these two test conditions, respectively. Five participants (45%) in the iAMD
group had RITs >20 minutes for 76% bleach at 58, but none for any other test condition.
CONCLUSIONS. Nearly half of the participants with iAMD produced unacceptably long recovery
times (>20 minutes) using a 76% bleach at 58 eccentricity. The 76% bleach at 128 provided
almost equivalent separation between AMD and controls but recovery was achieved within 20
minutes.
Keywords: dark adaptation, age-related macular degeneration, rod intercept time
AMD remains the leading cause of blindness in developedcountries, despite the advent of anti-vascular endothelial
growth factor therapy to treat the neovascular form of the
condition.1–4 The advanced forms of AMD are associated with a
debilitating loss of central vision, impacting on ability to
perform activities of daily living,5,6 quality of life,5,7–9 well-
being and mood,5,10,11 social participation,12 and risk of
falls.13–15 A key aim of future interventions must be to prevent
the progression to this end stage in people with intermediate
AMD. Sensitive biomarkers of disease progression have the
potential to facilitate cost-effective evaluation of new interven-
tions.16,17
The time taken for rods to dark adapt, assessed using an
adaptometer (AdaptDX; Maculogix, Middletown, PA, USA), has
been shown to progressively increase with increasing severity
of AMD, suggesting that it has potential as a biomarker for
disease progression.18–21 However, substantial longitudinal data
are required to confirm the clinical utility of the test in this
capacity. The test records the so-called ‘rod intercept time’
(RIT; i.e., time taken to reach a threshold located within the
second component of rod recovery).19 Previous studies have
mainly aimed to develop a diagnostic test using the device,
whereby it is appropriate to designate individuals as ‘abnormal’
if RIT exceeds a criterion time.19,22–24 However, for longitudinal
evaluation, it is necessary to obtain an actual value for the rate
of rod adaptation, to allow assessment of progression.
Longitudinal studies are expensive to conduct, requiring a
large cohort of participants to be followed over a prolonged
period. As such, optimization of the dark adaptation test
protocol is necessary to ensure that maximum value is obtained
from future cohort studies. The optimal testing protocol would
obtain a valid RIT result within a clinically viable timeframe,
while maintaining sensitivity to disease progression. This may
be achieved by modifying test location or bleach intensity.
Previous studies have employed a 58 or 118/128 test locus in the
inferior field, with either an 82%, 83%, or 76% equivalent
photopigment bleach.18–29 Published data suggest that a 76%
bleach of rod photopigment is sufficient to highlight the AMD-
related deficit.19 One of the key issues is demonstrated by the
findings of Owsley et al.20 When recovery was recorded at a
location 118 in the inferior field of 30 individuals with iAMD
after a 76% equivalent rhodopsin bleach, 11 participants (37%)
had a RIT exceeding 20 minutes at baseline. A test protocol
which could reliably be completed within 20 minutes would be
preferable, given the restricted time available within clinical
environments. Given the known preferential damage of the
parafoveal retina in the earliest stages of AMD,30,31 the test
location of 58 is likely to provide greater sensitivity to the
earliest manifestation of the disease than the 128 location but at
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the expense of a longer testing time in those with more
advanced changes.
The aim of this study was to determine the optimal bleach
intensity and retinal location combination for the dark
adaptation assessment of people with iAMD.
METHODS
People with early AMD, iAMD, non-central geographic atrophy
and age-similar controls were recruited through advertisements
in the Macular Society Sideview magazine and by contacting a
database of research volunteers at City, University of London.
Additional control participants were recruited through an
advertisement posted in the International Glaucoma Associa-
tion magazine. Inclusion criteria included age >55 years,
sufficiently clear ocular media and adequate pupillary dilation
and fixation to permit quality fundus imaging (Grade 2 on the
LOCS III scale32), signs of AMD or healthy ageing (controls) in
test eye, best corrected visual acuity of 6/30 (logMAR 0.7) or
better in test eye. Participants were excluded if they had
received any previous treatment for AMD, any other retinal or
optic nerve pathology in the test eye (such as glaucoma),
significant systemic disease known to affect visual function, or
a history of medication known to affect visual function.
Participants were also excluded if they were unable to perform
the test. The participant information sheet was provided to all
participants at least 24 hours before the first study visit, and
each participant was given the opportunity to ask questions
before signing a consent form. Institutional research ethical
approval was obtained (School of Health Sciences, City,
University of London), and all procedures adhered to the
tenets of the Declaration of Helsinki.
Rod Intercept Time was assessed under five test conditions
over two visits (see Table 1). Test order was randomized. At
visit 1, a spectral domain optical coherence tomography (SD-
OCT) image was captured using the Spectralis device (308 3
208 volume scan, Heidelberg Engineering, Heidelberg, Ger-
many) in order to determine the AMD status of each eye before
selecting an eye for testing, without exposing the eyes to a
bright adapting light. A randomization schedule was used to
select the study eye if both were eligible for inclusion. After
structured history and symptoms, a brief objective and
subjective refraction took place and best corrected visual
acuity (BCVA) was measured on a letter-by-letter basis and
recorded as a recorded as a logMAR score for each eye using
the Early Treatment of Diabetic Retinopathy Study (ETDRS)
chart at 4 m.
After baseline data had been collected, the participant was
seated in a dark room for 30 minutes, during which time the
procedure was explained. The adaptometer (Maculogix)
measures and adjusts for pupil diameter, hence pupil dilation
was not required prior to testing. The RIT was then tested
using one of the test conditions (see Table 1), selected
according to the randomization schedule. When data collec-
tion for the first test was complete, a 30-minute washout and
rest period was provided, before conducting the second test.
Fundus photography was conducted on both eyes at the end of
the visit (308 field centered on the fovea; Topcon 3D OCT;
Topcon, Japan) to minimize the impact on the state of retinal
adaptation. If pupils were too small to allow adequate imaging
of the retina, pupils were dilated using tropicamide 1.0%.
Fundus photographs were graded for AMD severity by an
Optometrist grader (DT or LE) according to the Beckman
initiative severity scale,33 and OCT images were used to
confirm the presence/absence of features of advanced AMD.
The Beckman initiative scale comprises five stages; no
apparent aging changes, normal aging changes, early AMD,
intermediate AMD, and late AMD. Early AMD is characterized
by medium sized drusen (>63 lm and 125 lm in the absence
of pigmentary abnormalities), while intermediate AMD features
drusen > 125 lm and/or pigmentary abnormalities and late
AMD comprises either geographic atrophy or neovascular
AMD.
At the second visit, visual acuities were rechecked and the
participant questioned about any change in their ocular status.
Following an initial 30-minute period of dark adaptation, the
remaining three test conditions were assessed, again with a 30-
minute washout period between each.
Adaptometry Procedure
Before dark adaptation commenced, a spherical trial lens was
inserted into the lens holder of the adaptometer (þ3.00 DS þ
spherical distance prescription). The participant was instruct-
ed to place their head on the chinrest of the adaptometer, and
to focus on a 635-nm fixation light. An infrared camera
displayed the eye on a monitor. The examiner adjusted the
chin-rest position in order to achieve the correct centration of
the participant’s eye relative to the fixation target.
The pupil diameter was automatically measured prior to the
delivery of a 505-nm photoflash (~80 ms duration, equivalent
bleach described in Table 1). The luminance of the flash was
modified by the device to account for baseline pupil diameter
in producing a consistent retinal illuminance. The flash
subtended 48 and was centered at either 5 or 128 on the
inferior vertical meridian. The test stimulus was presented at
the same location as the bleach. Threshold was measured for a
28 diameter, 505 nm circular target, beginning 15 seconds after
the bleaching flash. The participant was instructed to maintain
fixation on the red fixation light and to press a response button
when a flashing target first became visible within the bleached
area. Threshold was estimated using a 3-down/1-up modified
staircase estimate procedure and continued at 30-second
intervals for 30 minutes or until the rod intercept was reached.
There was a 15-second rest period after each threshold was set.
If the RIT was not reached within the test, it was set at the
maximum test duration (30 minutes).
The device records the percentage of threshold points
which are suggestive of a fixation error. In this study, as in
previous reports,19 if fixation errors exceeded 30%, the test
was deemed unreliable. An additional potential source of error
was the bleach not being presented to the correct retinal
location, or while the eye was fully open. Participants were
invited to return for a third visit to repeat any unreliable tests.
If the results were not valid on repetition, then data were not
supplied for this test condition, but the remaining test results
were included in the analysis.
Analysis
Statistical analysis was carried out in a statistical environment
(IBM SPSS, version 25; IBM Corp., Armonk, NY, USA), and
TABLE 1. Test Parameters Used in Each Condition
Test
Equivalent
Rhodopsin
Bleach, %34,43
Bleach
Luminance
(scot cd/m2s) Location
1 76 1.8 3 104 58 inferiorly
2 70 5.8 3 103 58 inferiorly
3 65 2.4 3 103 58 inferiorly
4 76 1.8 3 104 128 inferiorly
5 70 5.8 3 103 128 inferiorly
Test order was randomized.
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graphs were constructed in spreadsheet software (Excel 2016;
Microsoft Corp., Redmond, WA, USA) and using the ggplot2
and pROC packages in R 3.4.3 (http://www.r-project.org/)
under R Studio, version 1.1.383 (RStudio, Boston, MA, USA).
The Shapiro-Wilk test was used to assess normality of data
distribution. Results were compared between those with and
without AMD (independent samples t-test or Mann-Whitney U
test for nonnormally distributed data), and ROC curves were
constructed in order to assess the sensitivity of the test
conditions to disease-related adaptational dysfunction. A 1-way
ANOVA test with post-hoc Bonferroni testing (or Kruskal Wallis
with post-hoc Mann-Whitney) was used to determine the
differences in RIT between test conditions within each group.
The proportion of participants failing to reach the RIT within a
20-minute window was also evaluated.
RESULTS
Twenty-six participants with variable grades of macular health
participated in the study (n¼ 10 controls, n¼ 2 early AMD, n
¼10 iAMD, n ¼ 4 geographic atrophy). The main analysis
consisted of a comparison between control and iAMD groups.
Early AMD and geographic atrophy data from individuals are
presented for comparison. Six other volunteers (four AMD, two
controls) were excluded due to inability to perform the test
reliably (repeated testing yielded fixation errors exceeding 30%
or inability to calculate the RIT). A further two individuals with
AMD withdrew after one visit, after finding the repeated
testing protocol too arduous. There was no significant
difference in age (mean controls: 69 years 6 8 SD; mean
iAMD: 71 years 6 8 SD, independent samples t-test, P¼ 0.73),
or in BCVA (mean controls: 0.15 6 0.15 SD, mean AMD: 0.17
6 0.19 SD, independent samples t-test, P ¼ 0.22) between
control participants and those with AMD. Details of each
participant are given in Table 2.
Figure 1 shows sample recovery data from three control
participants and three participants with iAMD for each test
condition. Recovery tended to be slower for participants with
iAMD, particularly for the 76% bleach condition. It was not
possible to obtain an accurate RIT from all participants for all
test conditions (see Table 2 for individual data). For the 65%
bleach condition, rod intercept could not be calculated for 14/
26 (54%) of tests as threshold recovered too rapidly. In
contrast, only 2/26 (8%) of tests were invalid at the 58 location
following a 76% bleach, and only 4/26 (15%) of tests were
invalid in the 128 location for the same bleach. With respect to
testing time, for five individuals with iAMD (45%) and one
control the RIT exceeded 20 minutes following a 76% bleach at
58 eccentricity. The RIT did not exceed 20 minutes for any
individual for any of the other test conditions.
The distributions of RIT for participants with iAMD and
controls are shown in Figure 2. Data from the individuals with
early AMD and geographic atrophy are shown for comparison.
Average recovery times were longer for participants with AMD
under all test conditions, with the greatest difference between
groups at the 58 location, following the 76% bleach. There was
a statistically significant difference in average RIT between the
controls and iAMD group for the 58 location following a 76%
bleach (median, IQR controls ¼ 5.8 minutes, 3.8–7.5; iAMD ¼
20.6 minutes, 11.1–30.0; Mann-Whitney U test, P ¼ 0.01) and
for the same bleach at the 128 location (mean, controls: 4.54
minutes 6 2.12 SD, iAMD ¼ 7.72 minutes 6 3.37 SD;
independent samples t-test, P ¼ 0.03). As expected, average
recovery times increased in each group with an increasing
proportion of photopigment bleached (Fig. 2). Recovery was
more rapid for the 128 location than the 58 location for any
given bleach intensity, especially for the AMD participants.
This was statistically significant for the 58 location, where the
76% bleach produced significantly longer RIT than any other
test condition (Kruskal Wallis, P < 0.001). The average
recovery time for the 58 location following a 76% bleach was
more than twice that at the 128 location following the same
magnitude of bleach for iAMD participants.
Receiver operating characteristics (ROC) curves were
constructed for those tests which differed significantly
between groups in the univariate analysis to determine the
ability of each test to differentiate between controls and people
with iAMD (see Fig. 3). The best separation between groups
was exhibited by the 76% bleach at 58 (area under the curve
[AUC]¼ 0.83, CI: 0.64–1.0), and the 76% bleach at 128 (AUC¼
0.79, 0.59–0.99 CI). For the 76% at 58 test condition, using the
published diagnostic cutoff for the RIT of 6.5 minutes,19 five
out of the eight control participants for whom valid data were
collected were correctly identified (63% specificity), while all
10 iAMD participants were correctly identified as abnormal
(100% sensitivity). For the 128 location, specificity remained at
63% (5/8 controls correctly identified) while sensitivity fell to
89% (8/9 AMD for whom data were available) for a 5.5-minute
optimal cutoff.
DISCUSSION
Participants with iAMD were of key interest in this exploratory
study. A control comparator group was included to ensure that
sensitivity to the disease related deficit was maintained. Dark
adaptation assessed using a 76% equivalent bleach at a location
58 in the inferior field provided optimal separation between
people with AMD, predominantly of the intermediate stage,
and healthy controls, but at the expense of a long recording
duration. An alternative test location at 128 in the inferior field
was still able to distinguish between groups in our sample of
data, but recording time was reduced by more than 50%.
Mean recovery time for people with iAMD in this study for
the 76% bleach at 58 was 19.9 minutes 6 10.6 SD. This was
broadly in alignment with the 16.6 minutes 6 5.2 SD reported
by Jackson et al. in their larger sample of 72 participants with
iAMD using the same test parameters.19 Owsley et al.20
reported a substantially longer recovery time in their cohort
of 30 participants with iAMD, assessed using a 76% bleach at
118 eccentricity (20.3 minutes 6 14.3 SD vs. 7.7 minutes 6 3.3
SD for the participants with iAMD in the current study). This is
likely to be due to the difference in severity grading between
studies. Owsley required multiple, large confluent drusen,
with or without focal pigmentary changes. In contrast, the
Beckman scale employed in the current study classifies a
patient as having iAMD if only one large druse is present.33
Furthermore, 21/30 (70%) of the participants in Owsley’s study
had advanced AMD in the fellow eye, compared to 3/10 (30%)
of participants with iAMD in the current study. The presence of
nAMD in the fellow eye has been reported to be associated
with an increased delay in RIT,21 so the increased proportion of
people with advanced disease in the fellow eye is likely to have
resulted in an increase in RIT in the previous study.
As reported in previous studies,19–21,23 we found a
substantial variation in the recovery times between people
with comparable retinal appearance. It has been reported that
the presence of any structural abnormality in the retinal testing
spot is associated with a significantly prolonged RIT during
dark adaptation assessment.26 Thus, the variability is likely to
reflect the topographical heterogeneity of the disease process
in AMD, and the focal nature of the test stimulus used in this
device. This variability in results was also high for the control
group. This is in alignment with the findings of Owsley et al.,23
who found that one quarter of 381 apparently macular healthy
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individuals had abnormally long dark adaptation times.23 This
was associated with known risk factors for AMD onset. The
possibility that the control group in the current study was
heterogenous is also indicated by the lower than expected
specificity of the 76% bleach at 58 test condition (63% vs. 90%
in a previous report19). It is possible that those whose
adaptation times extended beyond the 6.5-minute cutoff may
be found in future to have been at a sub-clinical stage of AMD
onset.
As in previous reports,20 we also found some individuals to
show a very rapid rate of recovery. In some cases, this resulted
in the inability of the device to calculate the RIT (see Table 2).
This is likely to reflect a loss in fixation or a blink of the
participant during the presentation of the bleach, resulting in a
failure to present the photoflash to the correct area of the
retina. As the bleaching flash subtends only 48, and the test
stimulus is 28 in diameter, a small eye movement of more than
18 degree in either direction during the presentation of the
bleach may result in the test stimulus being presented to an
unbleached area of the retina during the test. However, the
high number of cases of failures to calculate the rod intercept
for the lowest bleach (54% of tests were invalid for the 65%
equivalent bleaching flash), including otherwise compliant
participants, suggests that for this intensity even a correctly
aligned bleaching flash produced a recovery which was too
rapid to evaluate using this technology.
It is important to note that the aim of the current study was
to determine optimal testing conditions for evaluating people
with iAMD for longitudinal evaluation. As such, the inter-
participant variability and diagnostic accuracy is not of prime
importance as each individual will act as their own comparator
in longitudinal evaluation. However, some evidence that the
test is challenging the macula sufficiently to reveal AMD-related
deficits is required. This is why a comparison of average data
between AMD and control groups was carried out, as well as
the ROC analysis. On the basis of this analysis, which showed
very little separation between iAMD and control groups for the
70% and 65% bleach conditions, the lower bleach conditions
evaluated in this study would not be recommended for
longitudinal evaluation.
The earliest AMD related damage appears in the parafoveal
region, from 2 to 48 from fixation, decreasing steadily with
increasing eccentricity.30,31 On this basis, the 58 retinal
eccentricity would seem a more logical choice for longitudinal
evaluation of AMD than the 128 retinal location. However, this
study and others19,21,26 have demonstrated that the time taken
for people with iAMD to reach the rod intercept in the 58
location is substantial and may exceed 20 minutes in a quarter
or more of participants. Threshold measurement continues
throughout this time, which is fatiguing for patients (a factor
known to reduce performance in psychophysical tests35), and
is inconvenient and costly in terms of clinic time. Although the
128 location showed a slightly reduced separation between
groups in this study, the area under the ROC curve for our
sample of data remained high, suggesting that there is
sensitivity to disease-related dysfunction at this location, at
least for a cohort of people with iAMD. This is in accordance
with evidence that AMD related abnormalities extend beyond
the parafovea, especially as the disease progresses.20,30,36–40
For example, Owsley et al.40 demonstrated a significant deficit
TABLE 2. Clinical Characteristics of all Participants
Px ID
LogMAR
Test Eye
AMD Status
Test Eye
AMD Status
Fellow Eye
Rod Intercept Time/Min
58 at 65% 58 at 70% 58 at 76% 128 at 70% 128 at 76%
RR0013 0.16 1 1 1.6 3.5 6.5 2.9 7.5
ET0007 0.34 1 1 1.4 1.4 5.1 2.3 NC
JE0008 0.00 1 1 1.7 6.0 4.1 UD 6.3
KG0020 0.46 1 1 NC 3.3 UD 2.2 NC
JC0032 0.16 1 1 1.2 2.7 3.0 2.1 5.2
GM0035 0.04 1 1 NC 2.6 12.8 2.2 1.8
BW0037 0.00 1 1 NC 13.1 3.1 1.9 5.0
MI0033 0.16 1 1 NC 1.3 21.5† NC 2.7
SF0034 0.10 1 1 NC NC UD 0.9 2.0
FJ0038 0.16 1 1 NC 1.3 7.5 3.6 5.8
AG0002 0.20 2 2 NC 7.1 12.3 NC NC
KM0003 0.16 2 2 NC NC 14.5 NC 3.6
DH0005 0.44 3 3 1.7 1.5 10.8 2.6 2.6
MM0006 0.20 3 3 1.4 11.1 7.6 NC 6.7
GE0010 0.00 3 3 NC 3.5 12.0 2.9 6.8
PS0012 0.20 3 3 NC 4.2 30.0* UD 6.9
GD0014 0.04 3 3 NC UD 29.0† 1.5 6.0
VC0015 0.02 3 4 NC 2.1 30.0* 5.6 10.2
BB0016 0.42 3 4 0.9 1.3 30.0* NC NC
PN0009 0.06 3 4 1.2 11.2 7.3 2.0 5.9
JB0018 0.00 3 3 1.2 UD 12.3 3.9 10.1
WP0032 0.40 3 3 1.7 9.4 30.0* 2.2 14.4
JG0027 0.20 4 4 NC 10.0 4.6 NC 12.3
EC0011 0.44 4 4 1.8 1.5 10.6 2.1 8.7
AF0028 0.50 4 4 2.6 1.9 14.0 1.7 3.2
PF0031 0.12 4 4 NC 8.9 3.8 2.2 2.3
AMD status refers to the Beckman severity scale, where 1¼ no changes or normal aging changes, 2¼ early AMD, 3¼ iAMD, and 4¼ late AMD.33
NC indicates that rod intercept could not be calculated due to threshold dropping too rapidly to below 3.0 log units of stimulus attenuation (due to
insufficient bleach intensity or bleach ineffectively delivered), UD indicates unreliable data (fixation errors exceeding 30%).
* RIT was not reached within the maximum test duration, and a value of 30 minutes was ascribed.
† RIT exceeded the 20-minute optimal maximum test duration.
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in rod adaptation parameters in people with early AMD and
near normal VA at a locus 12 degrees on the vertical meridian.
Nguyen et al.38 in a study of retinotopic rod function showed
that, while the effect of the disease was greatest in the central
macula, as expected, there was a significant difference in RIT
between controls and people with iAMD at the 128 location.
Owsley et al.20 reported that, when RIT was evaluated at 118
eccentricity, 22 of 30 eyes (73.3%) with iAMD had an increase
in RIT exceeding 1 minute over a follow-up period of 24
months, and 17 of 30 eyes (56.7%) had an increase exceeding 3
minutes. This suggests that the 128 location is likely to be
sensitive to disease progression in people with iAMD.
However, this requires further longitudinal evaluation, and it
is still likely to be more appropriate to adopt the 58 location
when evaluating a cohort of individuals with early AMD who
are likely to proceed more rapidly with dark adaptation than
those with iAMD.19
The strength of this study is that, for the first time, a
comparison is made of the bleach recovery characteristics of
people with iAMD using different test protocols of the
adaptometer (Maculogix). This will assist future longitudinal
study design. One limitation of this study was that a relatively
high proportion of patients was unable to complete all test
conditions. It should be noted, however, that under clinical
trial conditions it would not be recommended to carry out
more than one trial in a session. Fatigue may have affected
performance in the current study, in which three consecutive
trials were recorded in a single visit, resulting in an increased
number of missing datasets. The sample size in this exploratory
study was, consequently, small. An additional limitation is that,
to minimize the participant burden in this study, a limited
FIGURE 1. Graph showing sample adaptometer (Maculogix) data for three controls (RR0013, JC0032, FJ0038) and three participants with iAMD
(WP0032, GE0010, VC0015). Arrows indicate the RIT for each participant, where it occurred within the 30-minute testing window. For example,
for participant GE0010 the rod intercept was too fast to evaluate using the 58 at 65% condition while the RIT for the 70% bleach at 58 was 3.5
minutes, the 76% bleach at 58 was 12 minutes, the 70% bleach at 128 was 2.9 minutes, and the 76% bleach at 128 was 6.8 minutes. The recovery
times for the participants with AMD tended to be longer, especially for the 76% bleach.
Assessing Dark Adaptation in People With Intermediate AMD IOVS j Special Issue j Vol. 59 j No. 4 j AMD118
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936839/ on 09/20/2018
FIGURE 2. Box-and-whisker plots showing distribution of rod intercept time data for all participants for all test conditions. The ends of the
whiskers are set at31.5 the IQR above the third quartile and below the first quartile. Values outside this range are shown as outliers (red and pink
stars). The ‘‘65%,’’ ‘‘70%’’ and ‘‘76%’’ bleach refer to the equivalent rhodopsin bleach applied before testing began, while the ‘‘58’’ and ‘‘128’’ refer to
the location in the inferior field at which the stimulus was presented (see Table 1 for test conditions). The blue and yellow circles present data from
individuals with early AMD and geographic atrophy, respectively, for comparison. There is no evidence from these individuals of a marked
prolongation in recovery time associated with GA, and there is a substantial spread of recovery times in these individuals, which is in keeping with
the variability of results in the main comparison groups.
FIGURE 3. ROC curves and AUC for test conditions which showed a significant difference in univariate analysis, showing ability to discriminate
between iAMD and controls for all RIT cutoff points.
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range of bleach intensities was explored. The range was
chosen after preliminary scoping studies which showed that
recovery following equivalent bleaches of less than 65% was
too rapid, and did not allow the reliable assessment of the RIT.
While studies using other methodologies have reported using
much lower bleaches to effectively assess individuals with
AMD,41,42 the psychophysical methods used have differed from
those employed by the adaptometer (Maculogix). Furthermore,
the bleaching levels calculated by the adaptometer (Maculogix)
are based on the equivalent bleach concept, consistent with
arguments first given by Pugh.34,43 This accounts for the fact
that it is not possible to bleach 100% of rhodopsin with a
photoflash, and that threshold recovery proceeds in a similar
fashion after a scotopic-energy equivalent photoflash and long
duration bleach, even though a substantially smaller propor-
tion of photopigment is bleached by the photoflash. The lower
proportional bleaches cited in some other studies,41,42 would
actually be higher when expressed as an equivalent bleach.
A final limitation of this study related to the lack of grading
for the presence or absence of subretinal drusenoid deposits
(SDD). This means that the iAMD group is likely to have
included a mixture of participants with and without this
clinical feature. Prevalence estimates for SDD vary depending
on the imaging techniques used, and the classification of AMD.
For example, in the Alienor study, using multimodal imaging,
the prevalence of SDD in people with early/intermediate AMD
was reported as ranging from 13% to 62.6% (in the absence and
presence of focal pigmentary changes, respectively).44 Analysis
of color fundus photographs and near-infrared images from the
Rotterdam study cohort revealed a prevalence of 35% for
individuals with soft drusen OR pigmentary changes, and
14.5% for those with soft drusen AND pigmentary changes.45
In the current study, as there is substantial evidence to suggest
that those with SDD will take longer to reach the rod
intercept,21,26 the composition of the group with respect to
SDD status is likely to have had an impact on the performance
characteristics under each test condition. Future studies
employing a higher proportion of participants with SDD may
find that the test conditions identified as optimal here require
an unacceptably long recovery time, while the 58 location may
provide a higher sensitivity to progression of disease-related
changes in a group which has a lower proportion of
participants with SDD than the current study. Grading scales
and most clinical trials of iAMD currently do not include SDD
as a grading or inclusion criterion. For example, NCT02848313
is a trial of subcutaneous elamipretide for iAMD, in which
iAMD is defined by the presence of large/medium sized drusen
with or without non-central geographic atrophy. Similarly, trials
NCT00776451 and NCT03349801 also make no mention of
SDD in their disease groupings for iAMD individuals. As the aim
of this study was specifically to determine the most appropri-
ate test for the longitudinal assessment of a heterogeneous
group of individuals with iAMD, such as that which might be
recruited into such a trial, subdividing according to their SDD
status fell outside of the remit of the current analysis. On the
basis of the imaging carried out, it was not possible to carry out
accurate retrospective SDD grading for included participants,
however it would be of value for future studies to compare the
dark adaptation performance of people with and without SDD
using the test parameters identified in this study.
To summarize, this exploratory study has demonstrated that
the RIT, when assessed at 128 in the inferior field after a 76%
equivalent bleach of rod photopigment, shows promise as a
clinical test for iAMD. This test combination was able to
provide valid results for most participants within a 20-minute
test window, while maintaining sensitivity to the disease-
related functional deficit.
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